FDA Expands Use of Dapagliflozin to Broader Range of HF FDA Expands Use of Dapagliflozin to Broader Range of HF

The SGLT2 inhibitor is now indicated for treatment of heart failure across the full spectrum of left-ventricular ejection fraction ― including HF with mildly reduced and preserved ejection fraction.Medscape Medical News
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology News Alert Source Type: news